Literature DB >> 33718896

Broad-Spectrum Antibiotics and Risk of Graft-versus-Host Disease in Pediatric Patients Undergoing Transplantation for Acute Leukemia: Association of Carbapenem Use with the Risk of Acute Graft-versus-Host Disease

Caitlin W Elgarten1,2, Yimei Li3, Kelly D Getz2,3, Michael Hemmer4, Yuan-Shung V Huang5, Matthew Hall6, Tao Wang7, Carrie L Kitko8, Madan H Jagasia9, Taiga Nishihori10, Hemant S Murthy11, Hasan Hashem12, Mitchell S Cairo13, Akshay Sharma14, Shahrukh K Hashmi15,16, Medhat Askar17, Amer Beitinjaneh18, Matthew S Kelly19, Jeffery J Auletta20, Sherif M Badawy21,22, Melissa Mavers23, Richard Aplenc1,2,3, Margaret L MacMillan24, Stephen R Spellman25, Mukta Arora26, Brian T Fisher2,3,27.   

Abstract

Variation in the gastrointestinal (GI) microbiota after hematopoietic cell transplantation (HCT) has been associated with acute graft-versus-host disease (aGVHD). Because antibiotics induce dysbiosis, we examined the association of broad-spectrum antibiotics with subsequent aGVHD risk in pediatric patients undergoing HCT for acute leukemia. We performed a retrospective analysis in a dataset merged from 2 sources: (1) the Center for International Blood and Marrow Transplant Research, an observational transplantation registry, and (2) the Pediatric Health Information Services, an administrative database from freestanding children's hospitals. We captured exposure to 3 classes of antibiotics used for empiric treatment of febrile neutropenia: (1) broad-spectrum cephalosporins, (2) antipseudomonal penicillins, and (3) carbapenems. The primary outcome was grade II-IV aGVHD; secondary outcomes were grade III-IV aGVHD and lower GI GVHD. The adjusted logistic regression model (full cohort) and time-to-event analysis (subcohort) included transplantation characteristics, GVHD risk factors, and adjunctive antibiotic exposures as covariates. The full cohort included 2550 patients at 36 centers; the subcohort included 1174 patients. In adjusted models, carbapenems were associated with an increased risk of grade II-IV aGVHD in the full cohort (adjusted odds ratio [aOR], 1.24; 95% confidence interval [CI], 1.02 to 1.51) and subcohort (sub hazard ratio [HR], 1.31; 95% CI, 0.99 to 1.72), as well as with an increased risk of grade III-IV aGVHD (subHR, 1.77; 95% CI, 1.25 to 2.52). Early carbapenem exposure (before day 0) especially impacted aGVHD risk. For antipseudomonal penicillins, the associations with aGVHD were in the direction of increased risk but were not statistically significant. There was no identified association between broad-spectrum cephalosporins and aGVHD. Carbapenems, more than other broad-spectrum antibiotics, should be used judiciously in pediatric HCT recipients to minimize aGVHD risk. Further research is needed to clarify the mechanism underlying this association.

Entities:  

Keywords:  acute graft versus host disease; antibiotics; carbapenems; pediatrics

Year:  2020        PMID: 33718896      PMCID: PMC7946150          DOI: 10.1016/j.jtct.2020.10.012

Source DB:  PubMed          Journal:  Transplant Cell Ther        ISSN: 2666-6367


  52 in total

1.  Core elements of hospital antibiotic stewardship programs from the Centers for Disease Control and Prevention.

Authors:  Loria A Pollack; Arjun Srinivasan
Journal:  Clin Infect Dis       Date:  2014-10-15       Impact factor: 9.079

2.  Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease.

Authors:  Robert R Jenq; Ying Taur; Sean M Devlin; Doris M Ponce; Jenna D Goldberg; Katya F Ahr; Eric R Littmann; Lilan Ling; Asia C Gobourne; Liza C Miller; Melissa D Docampo; Jonathan U Peled; Nicholas Arpaia; Justin R Cross; Tatanisha K Peets; Melissa A Lumish; Yusuke Shono; Jarrod A Dudakov; Hendrik Poeck; Alan M Hanash; Juliet N Barker; Miguel-Angel Perales; Sergio A Giralt; Eric G Pamer; Marcel R M van den Brink
Journal:  Biol Blood Marrow Transplant       Date:  2015-05-11       Impact factor: 5.742

3.  Alteration of the Intestinal Microbiota by Broad-Spectrum Antibiotic Use Correlates with the Occurrence of Intestinal Graft-versus-Host Disease.

Authors:  Sung-Eun Lee; Ji-Young Lim; Da-Bin Ryu; Tae Woo Kim; Sung Soo Park; Young-Woo Jeon; Jae-Ho Yoon; Byung-Sik Cho; Ki-Seong Eom; Yoo-Jin Kim; Hee-Je Kim; Seok Lee; Seok-Goo Cho; Dong-Wook Kim; Jong Wook Lee; Chong-Su Kim; Dong-Mi Shin; Chang-Ki Min
Journal:  Biol Blood Marrow Transplant       Date:  2019-06-10       Impact factor: 5.742

Review 4.  Prevention and Treatment of Acute Graft-versus-Host Disease in Children, Adolescents, and Young Adults.

Authors:  Erin Gatza; Pavan Reddy; Sung Won Choi
Journal:  Biol Blood Marrow Transplant       Date:  2020-01-11       Impact factor: 5.742

Review 5.  Antibiotic-Induced Changes in the Intestinal Microbiota and Disease.

Authors:  Simone Becattini; Ying Taur; Eric G Pamer
Journal:  Trends Mol Med       Date:  2016-05-10       Impact factor: 11.951

6.  Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome.

Authors:  Hedvig E Jakobsson; Cecilia Jernberg; Anders F Andersson; Maria Sjölund-Karlsson; Janet K Jansson; Lars Engstrand
Journal:  PLoS One       Date:  2010-03-24       Impact factor: 3.240

Review 7.  The Role of Purine Metabolites as DAMPs in Acute Graft-versus-Host Disease.

Authors:  Petya Apostolova; Robert Zeiser
Journal:  Front Immunol       Date:  2016-10-21       Impact factor: 7.561

Review 8.  Impact of antimicrobial therapy on the gut microbiome.

Authors:  Amira A Bhalodi; Tjitske S R van Engelen; Harjeet S Virk; W Joost Wiersinga
Journal:  J Antimicrob Chemother       Date:  2019-01-01       Impact factor: 5.790

Review 9.  Intestinal Microbiota Influence Immune Tolerance Post Allogeneic Hematopoietic Cell Transplantation and Intestinal GVHD.

Authors:  Natalie Köhler; Robert Zeiser
Journal:  Front Immunol       Date:  2019-01-17       Impact factor: 7.561

10.  The gut mycobiome: The overlooked constituent of clinical outcomes and treatment complications in patients with cancer and other immunosuppressive conditions.

Authors:  Jessica R Galloway-Peña; Dimitrios P Kontoyiannis
Journal:  PLoS Pathog       Date:  2020-04-02       Impact factor: 6.823

View more
  4 in total

1.  Mucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host disease.

Authors:  Eiko Hayase; Tomo Hayase; Mohamed A Jamal; Takahiko Miyama; Chia-Chi Chang; Miriam R Ortega; Saira S Ahmed; Jennifer L Karmouch; Christopher A Sanchez; Alexandria N Brown; Rawan K El-Himri; Ivonne I Flores; Lauren K McDaniel; Dung Pham; Taylor Halsey; Annette C Frenk; Valerie A Chapa; Brooke E Heckel; Yimei Jin; Wen-Bin Tsai; Rishika Prasad; Lin Tan; Lucas Veillon; Nadim J Ajami; Jennifer A Wargo; Jessica Galloway-Peña; Samuel Shelburne; Roy F Chemaly; Lauren Davey; Robert W P Glowacki; Chen Liu; Gabriela Rondon; Amin M Alousi; Jeffrey J Molldrem; Richard E Champlin; Elizabeth J Shpall; Raphael H Valdivia; Eric C Martens; Philip L Lorenzi; Robert R Jenq
Journal:  Cell       Date:  2022-09-29       Impact factor: 66.850

2.  Piperacillin/Tazobactam and Meropenem Use Increases the Risks for Acute Graft Rejection Following First Kidney Transplantation.

Authors:  Dayana Nasr; Mahmoudreza Moein; Stephanie Niforatos; Sandy Nasr; Mulham Ombada; Farzam Khokhar; Myera Shahnawaz; Bhavya Poudyal; Maroun Bou Zerdan; Dibyendu Dutta; Reza F Saidi; Seah H Lim
Journal:  J Clin Med       Date:  2022-05-11       Impact factor: 4.964

3.  Clostridium butyricum therapy for mild-moderate Clostridioides difficile infection and the impact of diabetes mellitus.

Authors:  Jen-Chieh Lee; Chun-Wei Chiu; Pei-Jane Tsai; Ching-Chi Lee; I-Hsiu Huang; Wen-Chien Ko; Yuan-Pin Hung
Journal:  Biosci Microbiota Food Health       Date:  2021-11-03

4.  Microbiota dynamics in a randomized trial of gut decontamination during allogeneic hematopoietic cell transplantation.

Authors:  Christopher J Severyn; Benjamin A Siranosian; Sandra Tian-Jiao Kong; Angel Moreno; Michelle M Li; Nan Chen; Christine N Duncan; Steven P Margossian; Leslie E Lehmann; Shan Sun; Tessa M Andermann; Olga Birbrayer; Sophie Silverstein; Carol G Reynolds; Soomin Kim; Niaz Banaei; Jerome Ritz; Anthony A Fodor; Wendy B London; Ami S Bhatt; Jennifer S Whangbo
Journal:  JCI Insight       Date:  2022-04-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.